SUMOylation targeting mitophagy in cardiovascular diseases

Area of Science:

• Biochemistry and Molecular Biology
• Cardiovascular Research
• Cellular Biology

Background:

• Small ubiquitin-like modifier (SUMO)ylation is a crucial posttranslational modification involved in regulating cellular processes.
• SUMOylation plays a significant role in the pathogenesis of various cardiovascular diseases, including cardiac hypertrophy, hypertension, atherosclerosis, and ischemia-reperfusion injury.
• Mitophagy, the selective degradation of damaged mitochondria, is intrinsically linked to mitochondrial dynamics and cardiovascular health.

Purpose of the Study:

• To systematically review the expression, regulation, and structure of SUMO molecules.
• To explore the biochemical functions of SUMOylation in mitophagy initiation and activation.
• To discuss the biological roles and mechanisms of SUMOylation in cardiovascular diseases, highlighting its dual roles and potential therapeutic strategies.

Main Methods:

• Systematic review of existing literature on SUMOylation, mitophagy, and cardiovascular diseases.
• Analysis of the regulatory mechanisms of SUMOylation by ligases such as SENP family proteins, PIAS1, PIASy/4, UBC9, and MAPL.
• Examination of how SUMOylation affects mitochondrial dynamics, including fusion and fission, by modifying key proteins like Fis1, OPA1, MFN1/2, and DRP1.

Main Results:

• SUMOylation regulates mitophagy activation and mitochondrial function/dynamics, influencing mitochondrial fusion and fission.
• SUMOylation impacts the stability and degradation of proteins critical for mitophagy, such as PINK1, SERCA2a, and DRP1.
• SUMOylation exhibits dual roles in cardiovascular disease development, potentially promoting or inhibiting adverse cardiac remodeling and dysfunction.

Conclusions:

• SUMOylation is a key regulator of mitophagy and mitochondrial dynamics, significantly contributing to the development and progression of cardiovascular diseases.
• Further research into the precise functions and mechanisms of SUMOylation in mitochondrial dysfunction and mitophagy is warranted.
• Targeting SUMOylation and deSUMOylation pathways may offer novel therapeutic strategies for cardiovascular diseases.